MarketCap
Facebook
X
TelegramQuartalsbericht 2023-Q3
hinzugefügt 09.11.2023
Applied Molecular Transport Anteile 2011-2026 | AMTI
Anteile Jährlich Applied Molecular Transport
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.8 M | 37.6 M | 22.9 M | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 38.8 M | 22.9 M | 33.1 M |
Anteile Vierteljährlich Applied Molecular Transport
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39.8 M | 39.3 M | 39.2 M | 39.2 M | 38.9 M | 38.7 M | 38.6 M | 38.6 M | 38.4 M | 38.1 M | 35.2 M | 35.1 M | 34.8 M | 13.9 M | 7.42 M | 7.36 M | 7.36 M | 7.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 39.8 M | 7.36 M | 29.9 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
2.41 B | $ 3.72 | -3.38 % | $ 8.95 B |  Australia |
 |
I-Mab
IMAB
|
220 M | - | - | $ 866 M |  China |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 2.92 | - | $ 4.81 M |  Israel |
 |
AlloVir
ALVR
|
15.3 M | - | 4.14 % | $ 49.1 M |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
84.2 M | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
244 M | $ 95.5 | - | $ 27.2 B | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Precision BioSciences
DTIL
|
3.84 M | $ 6.67 | - | $ 25.6 M | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
208 M | $ 2.17 | - | $ 451 M | USA |
 |
Evogene Ltd.
EVGN
|
40.4 M | $ 0.81 | - | $ 27.9 M | Israel |
|
Forte Biosciences
FBRX
|
12.9 M | $ 35.09 | - | $ 454 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
46.7 M | $ 20.37 | - | $ 952 M | USA |
 |
Galectin Therapeutics
GALT
|
63.9 M | $ 2.3 | - | $ 147 M | USA |
 |
Acorda Therapeutics
ACOR
|
1.24 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
19.8 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
682 M | $ 8.21 | - | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
5.51 M | $ 0.37 | - | $ 2.04 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Halozyme Therapeutics
HALO
|
120 M | $ 67.82 | - | $ 8.13 B | USA |
 |
Celldex Therapeutics
CLDX
|
66.4 M | $ 32.24 | - | $ 2.14 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
257 M | $ 1.4 | - | $ 360 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
107 M | $ 4.08 | - | $ 436 M | USA |
 |
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
127 M | $ 24.21 | - | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |
 |
Hoth Therapeutics
HOTH
|
13.8 M | $ 0.52 | - | $ 7.18 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
266 M | $ 1.49 | - | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
6.35 M | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
44.3 M | - | 1083.1 % | $ 745 M | USA |
 |
ImmuCell Corporation
ICCC
|
9.03 M | $ 7.08 | -1.6 % | $ 63.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
6.28 M | $ 2.55 | - | $ 16 M | USA |
 |
Immutep Limited
IMMP
|
595 M | $ 0.31 | - | $ 1.08 B | Australia |
 |
InflaRx N.V.
IFRX
|
41.6 M | $ 1.0 | - | $ 152 M | Germany |
 |
Incyte Corporation
INCY
|
195 M | $ 96.07 | - | $ 18.8 B | USA |
 |
AstraZeneca PLC
AZN
|
1.42 B | - | - | $ 96.9 B | Britain |